Sign In
Buy EYPT
$12.25
-0.610 (-4.74%)
At Close: Jul 31, 2026
EyePoint Pharmaceuticals, Inc. (EYPT) CEO Nancy Lurker on Q1 2021 Results - Earnings Call Transcript
01:33pm, Wednesday, 05'th May 2021
EyePoint Pharmaceuticals, Inc. (EYPT) CEO Nancy Lurker on Q1 2021 Results - Earnings Call Transcript
EyePoint Pharmaceuticals's Earnings Outlook
10:34am, Tuesday, 04'th May 2021
On Wednesday, May 05, EyePoint Pharmaceuticals (NASDAQ:EYPT) will release its latest earnings report. Decipher the announcement with Benzinga's help.
EyePoint Pharmaceuticals End Of Year Earnings Call Analysis
02:51pm, Thursday, 22'nd Apr 2021
EyePoint Pharmaceuticals End Of Year Earnings Call Analysis
EyePoint Pharmaceuticals' (EYPT) CEO Nancy Lurker on Q4 2020 Results - Earnings Call Transcript
01:53pm, Thursday, 04'th Mar 2021
EyePoint Pharmaceuticals' (EYPT) CEO Nancy Lurker on Q4 2020 Results - Earnings Call Transcript
EyePoint Pharmaceuticals (EYPT) Reports Q4 Loss, Lags Revenue Estimates
09:08am, Thursday, 04'th Mar 2021
EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of -324.44% and -70.39%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for th
4 Stocks in the Limelight on New Analyst Coverage
10:36am, Wednesday, 17'th Feb 2021
Increased analyst coverage over the last few weeks might lead to solid price appreciation for stocks like Stamps.com Inc. (STMP), Ribbon Communications Inc. (RBBN), American Software, Inc. (AMSWA) and
EyePoint Pharmaceuticals: Time For Liftoff
08:54pm, Sunday, 14'th Feb 2021
EYPT has had great products for some time now. They finally got their financing in order and the market loved it.
EyePoint Pharmaceuticals Announces Closing of $115 Million Public Offering of Common Stock
12:29pm, Thursday, 04'th Feb 2021
WATERTOWN, Mass., Feb. 04, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the
EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock
04:01pm, Monday, 01'st Feb 2021
WATERTOWN, Mass., Feb. 01, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the
EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Trial of EYP-1901 for the Treatment of Wet AMD
07:00am, Thursday, 28'th Jan 2021
WATERTOWN, Mass., Jan. 28, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve th
EyePoint Pharmaceuticals Provides Business Update and Preliminary Fourth Quarter and Full-Year 2020 Net Product Revenues
04:01pm, Monday, 11'th Jan 2021
- IND filed in December 2020 for EYP-1901, a potential six-month sustained delivery intravitreal anti-VEGF treatment targeting wet age-related macular degeneration -
Week In Review: China Biopharma Starts 2021 With Over $1 Billion In Deals And IPOs
03:16pm, Sunday, 10'th Jan 2021
Gracell Biotech completed a $209 million NASDAQ IPO for its next-gen CAR-T treatments. Zai Lab acquired greater China rights to an argenx SE novel treatment for autoimmune indications in a deal worth
EyePoint Pharmaceuticals Announces $15.7 Million Equity Investment by Asia Partner Ocumension Therapeutics
07:00pm, Sunday, 03'rd Jan 2021
WATERTOWN, Mass., Jan. 03, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products,
EyePoint Pharmaceuticals Announces $16.5 Million Monetization of ILUVIEN® Royalty with SWK Holdings Corporation
07:00am, Friday, 18'th Dec 2020
WATERTOWN, Mass., Dec. 18, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative therapeutics to help
EyePoint Pharmaceuticals Announces 1-for-10 Reverse Stock Split
09:20am, Tuesday, 08'th Dec 2020
WATERTOWN, Mass., Dec. 08, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products,
